Press release

Demeditec Diagnostics GmbH enter into a distribution agreement with CardiNor for the CE marked CardiNor Secretoneurin ELISA


Kiel, Germany  and Oslo, Norway January 10, 2023: Cardiovascular DX company CardiNor AS today announces that it has signed an exclusive agreement with Demeditec for sales of the CE marked CardiNor Secretoneurin ELISA test in Germany. In addition, the agreement gives Demeditec the right to sell the test, on non-exclusive basis, in 15 countries outside Europe which includes India, South Korea, Mexico and Brazil.

The CardiNor Secretoneurin (SN) is a new biomarker test that could turn into a new gold-standard biomarker to monitor and treat millions of cardiac patients globally. SN has been shown to be a strong risk marker of mortality in several patient groups including ventricular arrhythmia, chronic heart failure and in patients with severe respiratory problems and sepsis. Thus, SN provides valuable prognostic information independent of established cardiovascular biomarkers.

Click here to view the product site of the Secretoneurin ELISA (Cat. No. 100-01).

Download the complete press release below!